Semaglutide's cardiovascular benefits: what the clinical evidence actually shows

Step 1: understanding what the SELECT trial actually measured

The cardiovascular case for semaglutide rests primarily on the SELECT trial, a double-blind, randomised, placebo-controlled study enrolling 17,604 adults across 33 countries. All participants had a BMI of 27 or above and established cardiovascular disease but no diabetes at enrolment. Over a median follow-up of around 3.3 years, those taking semaglutide 2.4mg once weekly had roughly a 20% lower rate of the primary endpoint (a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke) compared with the placebo group.

That number matters for a specific reason. Because the cohort excluded people with diabetes, the benefit cannot simply be explained by improved blood-glucose management. Researchers and regulators have since pointed to additional mechanisms: reductions in inflammation markers, improvements in blood pressure, and direct effects on arterial function that appear to occur independently of weight loss. The full picture is still being studied, but the trial result was robust enough that the MHRA granted Wegovy a cardiovascular risk-reduction licence on that basis alone.

You can read the NICE technology appraisal of semaglutide (TA875) for the committee's assessment of the evidence underpinning the weight-management recommendation, which draws on the same semaglutide clinical programme.

Step 2: what the cardiovascular licence covers, and what it does not

The UK cardiovascular indication for Wegovy applies to adults who meet all of the following: a BMI of 27 kg/m² or above, and an existing diagnosis of cardiovascular disease (typically meaning a prior heart attack, stroke, or peripheral arterial disease). It does not extend to people who simply have risk factors for heart disease without a confirmed diagnosis, and it is not a substitute for existing cardiovascular medicines such as statins or antihypertensives.

This distinction matters practically. A GP prescribing for cardiovascular risk reduction under this licence is doing something clinically distinct from prescribing for weight management, even though the medicine, dose and injection schedule are identical. Both indications are governed by the same prescribing framework: these are prescription-only medicines, suitability is assessed individually, and clinical monitoring continues throughout treatment.

If you want to understand how Wegovy supports cardiovascular health, including the SELECT trial findings, eligible populations and the regulatory pathway, that page covers the topic in full.

A quick check worth doing before your consultation: log the cardiovascular diagnoses in your medical history (heart attack, stroke, angina, PAD), because a prescriber will need these specifics to assess which indication, if either, applies to you. It takes under a minute and makes the clinical conversation far more efficient.

Step 3: how cardiovascular benefit sits alongside weight-management outcomes

In the SELECT trial, participants lost an average of around 9–10% of body weight on semaglutide over the study period, less than the roughly 15% seen in STEP 1, the dedicated weight-management trial, partly because the titration protocol differed. Yet the cardiovascular benefit appeared early, in some analyses before the bulk of weight loss had occurred. That timing has led researchers to investigate whether semaglutide's anti-inflammatory and direct vascular effects contribute independently.

For people with obesity and cardiovascular disease, the practical implication is that treatment may address two clinically important problems at once. If you are weighing up the full benefits of taking semaglutide, these include improvements in blood pressure, lipid profiles and markers of inflammation alongside the weight and cardiovascular endpoints. None of this replaces the lifestyle components (a reduced-calorie diet and increased activity remain part of the licensed framework) but the evidence base for semaglutide now extends well beyond waist circumference.

The MHRA's July 2026 conditional approval of Wegovy for MASH (metabolic dysfunction-associated steatohepatitis) adds another dimension: MASH carries significant cardiovascular risk in its own right, and semaglutide's conditional approval for that condition signals regulators' growing confidence in its metabolic reach.

Step 4: what this evidence means if you are considering Wegovy for weight management

Most people starting Wegovy do so for weight management rather than a confirmed cardiovascular indication. For those who also have cardiovascular disease, the SELECT data provides additional clinical rationale, something a prescriber can factor into their assessment. For those without established CVD, the weight-management evidence remains the primary basis for treatment, and our page on the semaglutide benefits for weight loss explains that evidence in plain terms.

Either way, the route is the same: a clinical consultation with a GPhC-registered prescriber who reviews your full health picture. The semaglutide overview page covers licensing, eligibility and what the consultation involves. If you are specifically weighing Wegovy against other options, the weight-loss treatment comparison lays out the landscape clearly.

The cardiovascular evidence is genuinely compelling, and it has changed how clinicians think about GLP-1 medicines. It has not, though, changed the fundamental requirement: semaglutide is a prescription medicine, and the decision to start, continue or adjust it rests with a qualified prescriber who knows your history. If you are ready to have that conversation, you can start your free consultation with our prescribers today.